NCT01469598

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

Phase II Study of Docetaxel and Gemcitabine in Previously Treated Metastatic Esophageal Squamous Cell Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Gemcitabine is a novel analog of the nucleoside deoxycytidine that acts via inhibition of DNA synthesis.Docetaxel is a semisynthetic taxane and promotes microtubule assembly and inhibits microtubule depolymerization. In this study, patients received gemcitabine 900 mg/m2 on days 1 and 8 plus docetaxel 100 mg/m2 on day 8 with G-CSF support every 3 week.

Conditions

• Metastatic Carcinoma
• Recurrent Esophageal Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Gemcitabine/Docetaxel	Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days

Timeline

• Start date: 2011-08-01
• Primary completion: 2014-02-01
• Completion: 2015-01-01
• First posted: 2011-11-10
• Last updated: 2015-12-29

Locations

1 site across 1 country: South Korea